The pandemic of the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
has been posing great threats to the world in many aspects. Effective therapeutic and …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has rapidly spread in
humans in almost every country, causing the disease COVID-19. Since the start of the …

Recent surveillance has revealed the emergence of the SARS-CoV-2 Omicron variant (BA.
1/B. 1.1. 529) harboring up to 36 mutations in spike protein, the target of neutralizing …

Vaccination elicits immune responses capable of potently neutralizing SARS-CoV-2.
However, ongoing surveillance has revealed the emergence of variants harboring mutations …

Abstract The coronavirus disease 2019 (COVID-19) pandemic presents an urgent health
crisis. Human neutralizing antibodies that target the host ACE2 receptor-binding domain …

Numerous antibodies that neutralize SARS-CoV-2 have been identified, and these generally
target either the receptor-binding domain (RBD) or the N-terminal domain (NTD) of the viral …

Summary Coronavirus disease 2019 (COVID-19) exhibits variable symptom severity ranging
from asymptomatic to life-threatening, yet the relationship between severity and the humoral …

SARS-CoV-2 is an enveloped virus responsible for the COVID-19 pandemic. Despite recent
advances in the structural elucidation of SARS-CoV-2 proteins, the detailed architecture of …

Targeting the interaction between the severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) spike protein and the human angiotensin-converting enzyme 2 (ACE2) …

Neutralizing antibody responses to coronaviruses mainly target the receptor-binding domain
(RBD) of the trimeric spike. Here, we characterized polyclonal immunoglobulin Gs (IgGs) …